🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to attend The American Association of Immunologists (AAI) #Immunology2024! If you are here, too, check out our #postdoc job posting on the job board (immunology2024.aai.org/job-posting/po…), and come see Thirumala-Devi Kanneganti present Sunday @ 1:15! Looking forward to seeing everyone and hearing all the exciting discoveries!

Come see our fearless leader and amazing mentor Thirumala-Devi Kanneganti present The American Association of Immunologists (AAI) #AAI2024 at 1:15 today in W375B! She’ll give an overview of her historic work and highlight some of our new, exciting findings! Excited to see everyone there!

New research by Thirumala-Devi Kanneganti in Cell reveals NLRC5 acts as an innate immune sensor and cell death regulator. This understanding has therapeutic implications for treating cancers, infectious diseases and inflammatory disorders. Read more ow.ly/kEPw50Sj8Tn

New resource for the field! #Protocol Current Protocols using genetic or inhibitor-based approaches to differentiate innate immune cell death pathways. Thanks for putting this together Rebecca Tweedell, Taylor Hibler, and Thirumala-Devi Kanneganti St. Jude Research! …rentprotocols.onlinelibrary.wiley.com/doi/10.1002/cp…

🔱🌊NLRC5 PANoptosome is Aquaman of the Dead Sea. Check out our Research Highlight Cell Research to see why! rdcu.be/dQg4G New research from Kanneganti Lab Thirumala-Devi Kanneganti St. Jude identified a new role for NLRC5 in cell death, inflammation&hemolytic disease Cell

It was great to work with Si Ming Man on this review for Nature Cell Biology to discuss how dying #cells are sensed and the physiological impact of how cells die. Significant implications across the #disease spectrum. Check it out! St. Jude Research

Excited for the FASEB #GTSCR meeting, which will be filled with great discussions about GI host-microbe interactions, inflammation, immunity, cancers, & more. If you are attending, come see Thirumala-Devi Kanneganti give the keynote address tomorrow evening!

Excited to see our review discussing inflammasomes in #health and #disease, including their roles in PANoptosomes & cell death, in Current Opinion in Immunology Elsevier Elsevier Immunology. Congrats Vinod & Thirumala-Devi Kanneganti! St. Jude Research pdf.sciencedirectassets.com/272032/1-s2.0-…

New research shows that disrupting the Asxl1 gene in T cells boosts response to immunotherapy and improves long-term tumor control by preventing T-cell exhaustion. Targeting Asxl1 may lead to more effective T cell-based immunotherapies. ow.ly/QbIg50TJeVq

Thrilled to announce our latest publication in Science Magazine describing a reverse-translation study that defines the core regulators of T cell stemness that can be exploited to improve immunotherapy! Tae Gun Kang, PhD St. Jude Research Stand Up To Cancer Van Andel Institute (VAI) science.org/doi/10.1126/sc…

Join us on 21st November for another exciting InflammaZoom session, where I'll be hosting Serge Mostowy (Mostowy Lab) and Prajwal Gurung for two exciting talks. Register here -events.abcam.com/event/inflamma…

🎊🥳Congratulations to everyone on the Highly Cited Researchers 2024 list Clarivate, but a special CONGRATS to the Kanneganti lab alumni/staff on the list: raju karki Si Ming Man RK Subbarao Malireddi (Mrk) We are so proud of you, and your impactful work!🎊🥳 #HighlyCited2024

Out today The Journal of Immunology from first authors Bhesh Raj Sharma & Mohi Choudhury: ✅NLRP3-dependent cell death occurs in CASP1- & GSDMD-deficient cells with LPS + ATP, suggesting cell death pathway other than pyroptosis ✅Led us to identify NLRP3-PANoptosome in WT cells academic.oup.com/jimmunol/advan…